Bourgeon Capital Management LLC Myovant Sciences Ltd. Transaction History

Bourgeon Capital Management LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 27, 2022	SELL	$7.78 - $14.69 $76,384 - $144,226	-9,818 Reduced 39.24%	15,200 $189,000
Q1 2022 May 03, 2022	BUY	$11.38 - $16.4 $32,637 - $47,035	2,868 Added 12.95%	25,018 $333,000
Q4 2021 Jan 31, 2022	BUY	$14.31 - $23.87 $114,480 - $190,960	8,000 Added 56.54%	22,150 $345,000
Q3 2021 Nov 09, 2021	SELL	$18.94 - $26.99 $4,735 - $6,747	-250 Reduced 1.74%	14,150 $318,000
Q2 2021 Jul 19, 2021	BUY	$17.07 - $24.56 $109,248 - $157,184	6,400 Added 80.0%	14,400 $328,000
Q1 2021 May 13, 2021	BUY	$20.46 - $25.18 $138,105 - $169,965	6,750 Added 540.0%	8,000 $165,000
Q4 2020 Jan 29, 2021	SELL	$13.8 - $27.62 $105,570 - $211,293	-7,650 Reduced 85.96%	1,250 $35,000
Q3 2020 Oct 28, 2020	BUY	$14.05 - $22.6 $125,045 - $201,140	8,900 New	8,900 $125,000

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of Bourgeon Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Bourgeon Capital Management LLC with notifications on news.